Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX ± BNT321 as adjuvant therapy in resected pancreatic adenocarcinoma
2023-506014-47-00Phase 2Withdrawn
- Sponsor
- BioNTech SE
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of MVT-5873 in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by BioNTech SE. Planned start Feb 2024; status: withdrawn.
02
Drugs
MVT-5873
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2023-506014-47-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506014-47-00.